Modeling the Effect of Binding Kinetics in Spatial Drug Distribution in the Brain

Overview

Journal Comput Math Methods Med

Publisher Hindawi

Specialty Medical Informatics

Date 2021 Jul 21

PMID 34285707

Authors

Nelson Kashaju

Mark Kimathi

Verdiana G Masanja

Affiliations

Soon will be listed here.

Abstract

A 3-dimensional mathematical model is developed to determine the effect of drug binding kinetics on the spatial distribution of a drug within the brain. The key components, namely, transport across the blood-brain barrier (BBB), drug distribution in the brain extracellular fluid (ECF), and drug binding kinetics are coupled with the bidirectional bulk flow of the brain ECF to enhance the visualization of drug concentration in the brain. The model is developed based on the cubical volume of a brain unit, which is a union of three subdomains: the brain ECF, the BBB, and the blood plasma. The model is a set of partial differential equations and the associated initial and boundary conditions through which the drug distribution process in the mentioned subdomains is described. Effects of drug binding kinetics are investigated by varying the binding parameter values for both nonspecific and specific binding sites. All variations of binding parameter values are discussed, and the results show the improved visualization of the effect of binding kinetics in the drug distribution within the brain. For more realistic visualization, we suggest incorporating more brain components that make up the large volume of the brain tissue.

References

Yamamoto Y, Valitalo P, van den Berg D, Hartman R, van den Brink W, Wong Y . A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. Pharm Res. 2016; 34(2):333-351. PMC: 5236087. DOI: 10.1007/s11095-016-2065-3. View

Hladky S, Barrand M . Fluid and ion transfer across the blood-brain and blood-cerebrospinal fluid barriers; a comparative account of mechanisms and roles. Fluids Barriers CNS. 2016; 13(1):19. PMC: 5508927. DOI: 10.1186/s12987-016-0040-3. View

Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M . Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res. 2006; 23(4):705-17. DOI: 10.1007/s11095-006-9780-0. View

Westerhout J, van den Berg D, Hartman R, Danhof M, de Lange E . Prediction of methotrexate CNS distribution in different species - influence of disease conditions. Eur J Pharm Sci. 2014; 57:11-24. DOI: 10.1016/j.ejps.2013.12.020. View

Tata D, Anderson B . A new method for the investigation of capillary structure. J Neurosci Methods. 2002; 113(2):199-206. DOI: 10.1016/s0165-0270(01)00494-0. View

Pardridge W . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1):3-14. PMC: 539316. DOI: 10.1602/neurorx.2.1.3. View

Bickel U . How to measure drug transport across the blood-brain barrier. NeuroRx. 2005; 2(1):15-26. PMC: 539317. DOI: 10.1602/neurorx.2.1.15. View

Wong A, Ye M, Levy A, Rothstein J, Bergles D, Searson P . The blood-brain barrier: an engineering perspective. Front Neuroeng. 2013; 6:7. PMC: 3757302. DOI: 10.3389/fneng.2013.00007. View

Karbowski J . Scaling of brain metabolism and blood flow in relation to capillary and neural scaling. PLoS One. 2011; 6(10):e26709. PMC: 3203885. DOI: 10.1371/journal.pone.0026709. View

10.

Andreone B, Chow B, Tata A, Lacoste B, Ben-Zvi A, Bullock K . Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis. Neuron. 2017; 94(3):581-594.e5. PMC: 5474951. DOI: 10.1016/j.neuron.2017.03.043. View

11.

Westerhout J, Smeets J, Danhof M, de Lange E . The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn. 2013; 40(3):327-42. PMC: 4269305. DOI: 10.1007/s10928-013-9314-4. View

12.

Vendel E, Rottschafer V, de Lange E . A 3D brain unit model to further improve prediction of local drug distribution within the brain. PLoS One. 2020; 15(9):e0238397. PMC: 7511021. DOI: 10.1371/journal.pone.0238397. View

13.

Nhan T, Burgess A, Lilge L, Hynynen K . Modeling localized delivery of Doxorubicin to the brain following focused ultrasound enhanced blood-brain barrier permeability. Phys Med Biol. 2014; 59(20):5987-6004. DOI: 10.1088/0031-9155/59/20/5987. View

14.

Schlageter K, Molnar P, Lapin G, Groothuis D . Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res. 1999; 58(3):312-28. DOI: 10.1006/mvre.1999.2188. View

15.

Upadhyay R . Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014; 2014:869269. PMC: 4127280. DOI: 10.1155/2014/869269. View

16.

de Witte W, Danhof M, van der Graaf P, de Lange E . In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. Trends Pharmacol Sci. 2016; 37(10):831-842. DOI: 10.1016/j.tips.2016.06.008. View

17.

Fenstermacher J, Kaye T . Drug "diffusion" within the brain. Ann N Y Acad Sci. 1988; 531:29-39. DOI: 10.1111/j.1749-6632.1988.tb31809.x. View

18.

Sweeney M, Zhao Z, Montagne A, Nelson A, Zlokovic B . Blood-Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2018; 99(1):21-78. PMC: 6335099. DOI: 10.1152/physrev.00050.2017. View

19.

Nicholson C, Chen K, Hrabetova S, Tao L . Diffusion of molecules in brain extracellular space: theory and experiment. Prog Brain Res. 2000; 125:129-54. DOI: 10.1016/S0079-6123(00)25007-3. View

20.

Olivier J . Drug transport to brain with targeted nanoparticles. NeuroRx. 2005; 2(1):108-19. PMC: 539329. DOI: 10.1602/neurorx.2.1.108. View